Advertisement

Pharmacogenetics of Asthma

  • Gregory A. Hawkins
  • Stephen P. Peters
Part of the Methods in Molecular Biology™ book series (MIMB, volume 448)

Summary

Asthma is a common disease characterized by airway inflammation and bronchorestriction. There are several common categories of medications for treating asthma; however, not all asthmatics have the same response to these medications, some of which are adverse responses that are potentially life threatening. Because interindividual responses to asthma medications can vary considerably, the potential for genetic contributions to variable drug responses is significant. This chapter reviews the most common biological pathways targeted by asthma therapy and briefly discusses the genetic contribution to varied responses to asthma therapy for four common types of asthma medications: β-agonists, anticholinergics, leukotriene modifiers, and corticosteroids.

Keywords

Anticholinergics asthma β-agonist corticosteroids drug response genetic association leukotriene polymorphisms 

References

  1. 1.
    Busse WW, Lemanske RF Jr. (2001) Asthma. N Engl J Med. 344, 350–362.PubMedGoogle Scholar
  2. 2.
    Koppelman GH, Meijer GG, Postma DS. (1999) Defining asthma in genetic studies. Clin Exp Allergy. 29(suppl. 4), 1–4.PubMedGoogle Scholar
  3. 3.
    Panhuysen CI, Meyers DA, Postma DS, Bleecker ER. (1995) The genetics of asthma and atopy. Allergy, 50, 863–869.PubMedGoogle Scholar
  4. 4.
    Tattersfield AE, Knox AJ, Britton JR, Hall IP. (2002) Asthma. Lancet. 360, 1313–1322.PubMedGoogle Scholar
  5. 5.
    Braman SS. (2006) The global burden of asthma. Chest. 130(1 suppl.), 4S–12S.PubMedGoogle Scholar
  6. 6.
    Masoli M, Fabian D, Holt S, Beasley R. (2004) The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 59, 469–478.PubMedGoogle Scholar
  7. 7.
    National Asthma Education and Prevention Program. (1997) Expert panel report 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health. NIH publication 97–4051.Google Scholar
  8. 8.
    National Asthma Education and Prevention Program. (2002) Executive summary of the NAREPP expert panel report. Guidelines for the diagnosis and management of asthma. Update on selected topics 2002. Bethesda, MD: National Institutes of Health. NIH publication 02–5075.Google Scholar
  9. 9.
    Drazen JM, Silverman EK, Lee TH. (2000) Heterogeneity of therapeutic responses in asthma. Br Med Bull. 56, 1054–1070.PubMedGoogle Scholar
  10. 10.
    Weiss ST, Litonjua AA, Lange C et al. (2006) Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J. 6, 311–326.PubMedGoogle Scholar
  11. 11.
    Israel E, Drazen JM, Liggett SB, et al. (2001) Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol. 124, 183–186.PubMedGoogle Scholar
  12. 12.
    Eichelbaum M, Ingelman-Sundberg M, Evans WE. (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med. 57, 119–137.PubMedGoogle Scholar
  13. 13.
    Drazen JM, Yandava CN, Dube L, et al. (1999) Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 22, 168–170.PubMedGoogle Scholar
  14. 14.
    Loke TK, Sousa AR, Corrigan CJ, Lee TH. (2002) Glucocorticoid-resistant asthma. Curr Allergy Asthma Rep. 2, 144–150.PubMedGoogle Scholar
  15. 15.
    Sampson AP, Siddiqui S, Buchanan D, et al. (2000) Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 55(suppl. 2), S28S31.PubMedGoogle Scholar
  16. 16.
    Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. (2000) Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor betaisoform. J Allergy Clin Immunol. 105, 943–950.PubMedGoogle Scholar
  17. 17.
    Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. (1999) Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann Intern Med. 130, 487–495.PubMedGoogle Scholar
  18. 18.
    Liggett SB. (2001) Pharmacogenetic applications of the Human Genome project. Nat Med. 7, 281–283.PubMedGoogle Scholar
  19. 19.
    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 129, 15–26.PubMedGoogle Scholar
  20. 20.
    Sears MR, Taylor DR. (1993) Bronchodilator treatment in asthma. Increase in deaths during salmeterol treatment unexplained. BMJ. 306, 1610–1611.PubMedGoogle Scholar
  21. 21.
    Taylor DR, Sears MR, Herbison GP, et al. (1993) Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax. 48, 134–138.PubMedGoogle Scholar
  22. 22.
    Taylor DR, Sears MR. (1994) Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest. 106, 552–559.PubMedGoogle Scholar
  23. 23.
    Lanes SF, Garcia Rodriguez LA, Huerta C. (2002) Respiratory medications and risk of asthma death. Thorax. 57, 683–686.PubMedGoogle Scholar
  24. 24.
    Lanes SF, Lanza LL, Wentworth CE, III. (1998) Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med. 158, 857–861.PubMedGoogle Scholar
  25. 25.
    Rea HH, Garrett JE, Lanes SF, Birmann BM, Kolbe J. (1996) The association between asthma drugs and severe life-threatening attacks. Chest. 110, 1446–1451.PubMedGoogle Scholar
  26. 26.
    Garrett JE, Lanes SF, Kolbe J, Rea HH. (1996) Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax. 51, 1093–1099.PubMedGoogle Scholar
  27. 27.
    Poole C, Lanes SF, Walker AM. (1990) Fenoterol and fatal asthma. Lancet. 335, 920.PubMedGoogle Scholar
  28. 28.
    Tantisira KG, Drazen JM. (2005) Pharmacogenetics. In: Silverman EK, Shapiro SD, Lomas DA, Weiss ST, eds. Respiratory genetics. London: Hodder Education; 191–216.Google Scholar
  29. 29.
    Dawson B., Trapp RG. (2004) Research questions about means in three of more groups. Basic and clinical biostatistics. 4th ed. New York: Lange Medical Books/McGraw-Hill; 162–189.Google Scholar
  30. 30.
    Magi R, Kaplinski L, Remm M. (2006) The whole genome tagSNP selection and transferability among HapMap populations. Pac Symp Biocomput. 535–543.Google Scholar
  31. 31.
    Brooks LD. (2006) Using the HapMap in drug development. Clin Adv Hematol Oncol. 4, 423–424.PubMedGoogle Scholar
  32. 32.
    Barnes MR. (2006) Navigating the HapMap. Brief Bioinform. 7, 211–224.PubMedGoogle Scholar
  33. 33.
    O'Shaughnessy KM. (2006) HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol. 61, 783–786.PubMedGoogle Scholar
  34. 34.
    Andrawiss M. (2005) First phase of HapMap project already helping drug discovery. Nat Rev Drug Discov. 4, 947.PubMedGoogle Scholar
  35. 35.
    Lin M, Aquilante C, Johnson JA, Wu R. (2005) Sequencing drug response with HapMap. Pharmacogenomics J. 5, 149–156.PubMedGoogle Scholar
  36. 36.
    Barrett JC, Fry B, Maller J, Daly MJ. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 21, 263–265.PubMedGoogle Scholar
  37. 37.
    Kraft P. (2006) Efficient two-stage genome-wide association designs based on false positive report probabilities. Pac Symp Biocomput. 523–534.Google Scholar
  38. 38.
    Wiltshire S, de Bakker PI, Daly MJ. (2006) The value of gene-based selection of tag SNPs in genome-wide association studies. Eur J Hum Genet. 14, 1209–1214.PubMedGoogle Scholar
  39. 39.
    Wang H, Thomas DC, Pe'er I, Stram DO. (2006) Optimal two-stage genotyping designs for genome-wide association scans. Genet Epidemiol. 30, 356–368.PubMedGoogle Scholar
  40. 40.
    Hirschhorn JN, Daly MJ. (2005) Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 6, 95–108.PubMedGoogle Scholar
  41. 41.
    Saito A, Kamatani N. (2002) Strategies for genome-wide association studies: optimization of study designs by the stepwise focusing method. J Hum Genet. 47, 360–365.PubMedGoogle Scholar
  42. 42.
    Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. (2001) A high-throughput SNP typing system for genome-wide association studies. J Hum Genet. 46, 471–477.PubMedGoogle Scholar
  43. 43.
    Barrett JC, Cardon LR. (2006) Evaluating coverage of genome-wide association studies. Nat Genet. 38, 659–662.PubMedGoogle Scholar
  44. 44.
    Evans DM, Cardon LR. (2006) Genome-wide association: a promising start to a long race. Trends Genet. 22, 350–354.PubMedGoogle Scholar
  45. 45.
    Yang Q, Cui J, Chazaro I, Cupples LA, Demissie S. (2005) Power and type I error rate of false discovery rate approaches in genome-wide association studies. BMC Genet. 6(suppl 1), S134.PubMedGoogle Scholar
  46. 46.
    Wang WY, Barratt BJ, Clayton DG, Todd JA. (2005) Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet. 6, 109–118.PubMedGoogle Scholar
  47. 47.
    Hawkins GA, Tantisira K, Meyers DA, et al. (2006) Sequence, haplotype and association analysis of ADR{beta}2 in multi-ethnic asthma case/control subjects. Am J Respir Crit Care Med. 174, 1101–1109.PubMedGoogle Scholar
  48. 48.
    Reihsaus E, Innis M, MacIntyre N, Liggett SB. (1993) Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 8, 334–339.PubMedGoogle Scholar
  49. 49.
    Green SA, Turki J, Innis M, Liggett SB. (1994) Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 33, 9414–9419.PubMedGoogle Scholar
  50. 50.
    Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. (1997) Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 100, 3184–3188.PubMedGoogle Scholar
  51. 51.
    Cho SH, Oh SY, Bahn JW, et al. (2005) Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of betaadrenoceptor gene. Clin Exp Allergy. 35, 1162–1167.PubMedGoogle Scholar
  52. 52.
    Kotani Y, Nishimura Y, Maeda H, Yokoyama M. (1999) Beta2-Adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma. 36, 583–590.PubMedGoogle Scholar
  53. 53.
    Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. (1999) Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther. 65, 519–525.PubMedGoogle Scholar
  54. 54.
    Tan S, Hall IP, Dewar J, Dow E, Lipworth B. (1997) Association between beta 2-adrenocep-tor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350, 995–999.PubMedGoogle Scholar
  55. 55.
    Hancox RJ, Sears MR, Taylor DR. (1998) Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J. 11, 589–593.PubMedGoogle Scholar
  56. 56.
    Israel E, Chinchilli VM, Ford JG, et al. (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 364, 1505–1512.PubMedGoogle Scholar
  57. 57.
    Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. (2000) Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 55, 762–767.PubMedGoogle Scholar
  58. 58.
    Israel E, Drazen JM, Liggett SB, et al. (2000) The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 162, 75–80.PubMedGoogle Scholar
  59. 59.
    Burchard EG, Avila PC, Nazario S, et al. (2004) Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. Am J Respir Crit Care Med. 169, 386–392.PubMedGoogle Scholar
  60. 60.
    Choudhry S, Ung N, Avila PC, et al. (2005) Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med. 171, 563–570.PubMedGoogle Scholar
  61. 61.
    Drysdale CM, McGraw DW, Stack CB, et al. (2000) Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 97, 10483–10488.PubMedGoogle Scholar
  62. 62.
    Johnatty SE, Abdellatif M, Shimmin L, Clark RB, Boerwinkle E. (2002) Beta 2 adrenergic receptor 5' haplotypes influence promoter activity. Br J Pharmacol. 137, 1213–1216.PubMedGoogle Scholar
  63. 63.
    McGraw DW, Forbes SL, Kramer LA, Liggett SB. (1998) Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 102, 1927–1932.PubMedGoogle Scholar
  64. 64.
    McGraw DW, Liggett SB. (1999) Coding block and 5 leader cistron polymorphisms of the beta2-adrenergic receptor. Clin Exp Allergy. 29(suppl. 4), 43–45.PubMedGoogle Scholar
  65. 65.
    Parola AL, Kobilka BK. (1994) The peptide product of a 5′ leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 269, 4497–4505.PubMedGoogle Scholar
  66. 66.
    Scott MG, Swan C, Wheatley AP, Hall IP. (1999) Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br J Pharmacol. 126, 841–844.PubMedGoogle Scholar
  67. 67.
    Timmermann B, Li GH, Luft FC, Lund-Johansen P, Skrabal F, Hoehe MR. (1998) Novel DNA sequence differences in the beta2-adrenergic receptor gene promoter region. Hum Mutat. 11, 343–344.PubMedGoogle Scholar
  68. 68.
    Taylor DR, Epton MJ, Kennedy MA, et al. (2005) Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med. 172, 700–703.PubMedGoogle Scholar
  69. 69.
    Dishy V, Landau R, Sofowora GG, et al. (2004) Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics. 14, 517–522.PubMedGoogle Scholar
  70. 70.
    Fenech A, Hall IP. (2002) Pharmacogenetics of asthma. Br J Clin Pharmacol. 53, 3–15.PubMedGoogle Scholar
  71. 71.
    Fenech AG, Ebejer MJ, Felice AE, Ellul-Micallef R, Hall IP. (2001) Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects. Br J Pharmacol. 133, 43–48.PubMedGoogle Scholar
  72. 72.
    Wang JC, Hinrichs AL, Stock H, et al. (2004) Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet. 13, 1903–1911.PubMedGoogle Scholar
  73. 73.
    Donfack J, Kogut P, Forsythe S, Solway J, Ober C. (2003) Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy. J Allergy Clin Immunol. 111, 527–532.PubMedGoogle Scholar
  74. 74.
    Yamamoto T, Yamashita N, Kuwabara M, et al. (2002) Mutation screening of the muscarinic m2 and m3 receptor genes in asthmatics, outgrow subjects, and normal controls. Ann Genet. 45, 109–113.PubMedGoogle Scholar
  75. 75.
    tera-Wadleigh SD, Wiesch D, Bonner TI. (1989) An SstI polymorphism for the human muscarinic acetylcholine receptor gene, m4 (CHRM 4). Nucleic Acids Res. 17, 6431.Google Scholar
  76. 76.
    McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. (2003) Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest. 112, 619–626.PubMedGoogle Scholar
  77. 77.
    Szalai C, Tolgyesi G, Nagy A, Falus A. (2006) Pharmacogenomics of asthma: present and perspective. Orv Hetil. 147, 159–169.PubMedGoogle Scholar
  78. 78.
    Israel E. (2005) Genetics and the variability of treatment response in asthma. J Allergy Clin Immunol. 115(4 suppl.), S532–S538.PubMedGoogle Scholar
  79. 79.
    Samuelsson B, Funk CD. (1989) Enzymes involved in the biosynthesis of leukotriene B4. J Biol Chem. 264, 19469–19472.PubMedGoogle Scholar
  80. 80.
    Samuelsson B, Haeggstrom JZ, Wetterholm A. (1991) Leukotriene biosynthesis. Ann N Y Acad Sci. 629, 89–99.PubMedGoogle Scholar
  81. 81.
    Drazen JM. (1995) Leukotrienes. In: Busse W.W., Holgate ST, eds. Asthma and rhinitis. Boston: Blackwell Scientific; 838–850.Google Scholar
  82. 82.
    Hall IP. (2000) Pharmacogenetics of asthma. Eur Respir J. 15, 449–451.PubMedGoogle Scholar
  83. 83.
    Hui Y, Funk CD. (2002) Cysteinyl leukotriene receptors. Biochem Pharmacol. 64, 1549–1557.PubMedGoogle Scholar
  84. 84.
    Coffey M, Peters-Golden M. (2003) Extending the understanding of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 3, 57–63.PubMedGoogle Scholar
  85. 85.
    Corrigan C, Mallett K, Ying S, et al. (2005) Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol. 115, 316–322.PubMedGoogle Scholar
  86. 86.
    Fukai H, Ogasawara Y, Migita O, et al. (2004) Association between a polymorphism in cysteinyl leukotriene receptor 2 on chromosome 13q14 and atopic asthma. Pharmacogenetics. 14, 683–690.PubMedGoogle Scholar
  87. 87.
    Hao L, Sayers I, Cakebread JA, et al. (2006) The cysteinyl-leukotriene type 1 receptor polymorphism 927T/C is associated with atopy severity but not with asthma. Clin Exp Allergy. 36, 735–741.PubMedGoogle Scholar
  88. 88.
    Kim SH, Oh JM, Kim YS, et al. (2006) Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy. 36, 433–439.PubMedGoogle Scholar
  89. 89.
    Park JS, Chang HS, Park CS, et al. (2005) Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics. 15, 483–492.PubMedGoogle Scholar
  90. 90.
    Pillai SG, Cousens DJ, Barnes AA, et al. (2004) A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics. 14, 627–633.PubMedGoogle Scholar
  91. 91.
    Zhang J, Migita O, Koga M, Shibasaki M, Arinami T, Noguchi E. (2006) Determination of structure and transcriptional regulation of CYSLTR1 and an association study with asthma and rhinitis. Pediatr Allergy Immunol. 17, 242–249.PubMedGoogle Scholar
  92. 92.
    Lima JJ, Zhang S, Grant A, et al. (2006) Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 173, 379–385.PubMedGoogle Scholar
  93. 93.
    Jampilek J, Dolezal M, Opletalova V, Hartl J. (2006) 5-Lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents. Curr Med Chem. 13, 117–129.PubMedGoogle Scholar
  94. 94.
    Brock TG. (2005) Regulating leukotriene synthesis: the role of nuclear 5-lipoxygenase. J Cell Biochem. 96, 1203–1211.PubMedGoogle Scholar
  95. 95.
    Sayers I, Barton S, Rorke S, et al. (2003) Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy. 33, 1103–1110.PubMedGoogle Scholar
  96. 96.
    Zhang WL, Yang XM, Shi J, Sun K, Hui RT. (2006) Polymorphism of SG13S114T/A in the ALOX5AP gene and the risk for stroke in a large Chinese cohort. Yi Chuan Xue Bao. 33, 678–684.PubMedGoogle Scholar
  97. 97.
    Manev H, Manev R. (2006) 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. Med Hypotheses. 66, 501–503.PubMedGoogle Scholar
  98. 98.
    Kaaman M, Ryden M, Axelsson T, et al. (2006) ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance. Int J Obes (Lond). 30, 447–452.Google Scholar
  99. 99.
    Kedda MA, Worsley P, Shi J, Phelps S, Duffy D, Thompson PJ. (2005) Polymorphisms in the 5-lipoxygenase activating protein (ALOX5AP) gene are not associated with asthma in an Australian population. Clin Exp Allergy. 35, 332–338.PubMedGoogle Scholar
  100. 100.
    Lohmussaar E, Gschwendtner A, Mueller JC, et al. (2005) ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke. 36, 731–736.PubMedGoogle Scholar
  101. 101.
    Ben-Asher E, Lancet D. (2004) 5-Lipoxygenase activating protein (ALOX5AP): association with cardiovascular infarction and stroke. Isr Med Assoc J. 6, 318–319.PubMedGoogle Scholar
  102. 102.
    Visvikis-Siest S, Marteau JB. (2006) Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol. 17, 139–151.PubMedGoogle Scholar
  103. 103.
    Kim SH, Park HS. (2006) Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J. 47, 15–21.PubMedGoogle Scholar
  104. 104.
    Kim SH, Choi JH, Holloway JW, et al. (2005) Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population. J Korean Med Sci. 20, 926–931.PubMedGoogle Scholar
  105. 105.
    Kim SH, Bae JS, Suh CH, Nahm DH, Holloway JW, Park HS. (2005) Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy. 60, 760–765.PubMedGoogle Scholar
  106. 106.
    Kim SH, Ye YM, Lee SK, Park HS. (2006) Genetic mechanism of aspirin-induced urticaria/ angioedema. Curr Opin Allergy Clin Immunol. 6, 266–270.PubMedGoogle Scholar
  107. 107.
    Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. (2006) Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev. 15, 502–508.PubMedGoogle Scholar
  108. 108.
    Kalayci O, Birben E, Sackesen C, et al. (2006) ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy. 61, 97–103.PubMedGoogle Scholar
  109. 109.
    Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. (2004) Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 25, 2467–2472.PubMedGoogle Scholar
  110. 110.
    Choi JH, Park HS, Oh HB, et al. (2004) Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet. 114, 337–344.PubMedGoogle Scholar
  111. 111.
    Samuelsson B, Hoshiko S, Radmark O. (1991) Characterization of the promoter of the human 5-lipoxygenase gene. Adv Prostaglandin Thromboxane Leukot Res. 21A, 1–8.PubMedGoogle Scholar
  112. 112.
    Hoshiko S, Radmark O, Samuelsson B. (1990) Characterization of the human 5-lipoxygenase gene promoter. Proc Natl Acad Sci U S A. 87, 9073–9077.PubMedGoogle Scholar
  113. 113.
    In KH, Silverman ES, Asano K, et al. (1999) Mutations in the human 5-lipoxygenase gene. Clin Rev Allergy Immunol. 17, 59–69.PubMedGoogle Scholar
  114. 114.
    In KH, Asano K, Beier D, et al. (1997) Naturally occurring mutations in the human 5lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 99, 1130–1137.PubMedGoogle Scholar
  115. 115.
    Currie GP, Lima JJ, Sylvester JE, Lee DK, Cockburn WJ, Lipworth BJ. (2003) Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol. 56, 422–426.PubMedGoogle Scholar
  116. 116.
    Isidoro-Garcia M, Davila I, Moreno E, Lorente F, Gonzalez-Sarmiento R. (2005) Analysis of the leukotriene C4 synthase A-444C promoter polymorphism in a Spanish population. J Allergy Clin Immunol. 115, 206–207.PubMedGoogle Scholar
  117. 117.
    Kawagishi Y, Mita H, Taniguchi M, et al. (2002) Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol. 109, 936–942.PubMedGoogle Scholar
  118. 118.
    Sanak M, Simon HU, Szczeklik A. (1997) Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet. 350, 1599–1600.PubMedGoogle Scholar
  119. 119.
    Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. (2000) Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol. 23, 290–296.PubMedGoogle Scholar
  120. 120.
    Sanak M, Szczeklik A. (2001) Leukotriene C4 synthase polymorphism and aspirin-induced asthma. J Allergy Clin Immunol. 107, 561–562.PubMedGoogle Scholar
  121. 121.
    Van SR, Stevenson DD, Baldasaro M, et al. (2000) 5 Flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol. 106(1 pt. 1), 72–76.Google Scholar
  122. 122.
    Sampson AP, Cowburn AS, Sladek K, et al. (1997) Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol. 113, 355–357.PubMedGoogle Scholar
  123. 123.
    Barnes PJ. (2006) Corticosteroids: the drugs to beat. Eur J Pharmacol. 533, 2–14.PubMedGoogle Scholar
  124. 124.
    Pratt WB, Toft DO. (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 18, 306–360.PubMedGoogle Scholar
  125. 125.
    Pratt WB, Gehring U, Toft DO. (1996) Molecular chaperoning of steroid hormone receptors. EXS. 77, 79–95.PubMedGoogle Scholar
  126. 126.
    Pratt WB, Morishima Y, Murphy M, Harrell M. (2006) Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol. (172), 111–138.Google Scholar
  127. 127.
    Chen S, Prapapanich V, Rimerman RA, Honore B, Smith DF. (1996) Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70. Mol Endocrinol. 10, 682–693.PubMedGoogle Scholar
  128. 128.
    Chen S, Smith DF. (1998) Hop as an adaptor in the heat shock protein 70 (hsp70) and hsp90 chaperone machinery. J Biol Chem. 273, 35194–35200.PubMedGoogle Scholar
  129. 129.
    Dittmar KD, Hutchison KA, Owens-Grillo JK, Pratt WB. (1996) Reconstitution of the steroid receptor.hsp90 heterocomplex assembly system of rabbit reticulocyte lysate. J Biol Chem. 271, 12833–12839.PubMedGoogle Scholar
  130. 130.
    Dittmar KD, Banach M, Galigniana MD, Pratt WB. (1998) The role of DNAJ-like proteins in glucocorticoid receptor.hsp90 heterocomplex assembly by the reconstituted hsp90.p60. hsp70 foldosome complex. J Biol Chem. 273, 7358–7366.PubMedGoogle Scholar
  131. 131.
    Grenert JP, Sullivan WP, Fadden P, et al. (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem. 272, 23843–23850.PubMedGoogle Scholar
  132. 132.
    Johnson BD, Schumacher RJ, Ross ED, Toft DO. (1998) Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem. 273, 3679–3686.PubMedGoogle Scholar
  133. 133.
    Mendel DB, Orti E. (1988) Isoform composition and stoichiometry of the approx 90-kDa heat shock protein associated with glucocorticoid receptors. J Biol Chem. 263, 6695–6702.PubMedGoogle Scholar
  134. 134.
    Minami Y, Kimura Y, Kawasaki H, Suzuki K, Yahara I. (1994) The carboxy-terminal region of mammalian HSP90 is required for its dimerization and function in vivo. Mol Cell Biol. 14, 1459–1464.PubMedGoogle Scholar
  135. 135.
    Pratt WB, Silverstein AM, Galigniana MD. (1999) A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37. Cell Signal. 11, 839–851.PubMedGoogle Scholar
  136. 136.
    Pratt WB, Galigniana MD, Harrell JM, DeFranco DB. (2004) Role of hsp90 and the hsp90binding immunophilins in signalling protein movement. Cell Signal. 16, 857–872.PubMedGoogle Scholar
  137. 137.
    Rogatsky I, Ivashkiv LB. (2006) Glucocorticoid modulation of cytokine signaling. Tissue Antigens. 68, 1–12.PubMedGoogle Scholar
  138. 138.
    Geserick C, Meyer HA, Haendler B. (2005) The role of DNA response elements as allosteric modulators of steroid receptor function. Mol Cell Endocrinol. 236, 1–7.PubMedGoogle Scholar
  139. 139.
    Cato AC, Schacke H, Sterry W, Asadullah K. (2004) The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy. 3, 347–353.PubMedGoogle Scholar
  140. 140.
    Schoneveld OJ, Gaemers IC, Lamers WH. (2004) Mechanisms of glucocorticoid signalling. Biochim Biophys Acta. 1680, 114–128.PubMedGoogle Scholar
  141. 141.
    Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 500, 51–62.Google Scholar
  142. 142.
    Breslin MB, Geng CD, Vedeckis WV. (2001) Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol Endocrinol. 15, 1381–1395.PubMedGoogle Scholar
  143. 143.
    Encio IJ, Detera-Wadleigh SD. (1991) The genomic structure of the human glucocorticoid receptor. J Biol Chem. 266, 7182–7188.PubMedGoogle Scholar
  144. 144.
    Francke U, Foellmer BE. (1989) The glucocorticoid receptor gene is in 5q31–q32. Genomics 4, 610–612.PubMedGoogle Scholar
  145. 145.
    Gehring U. (1993) The structure of glucocorticoid receptors. J Steroid Biochem Mol Biol. 45, 183–190.PubMedGoogle Scholar
  146. 146.
    Nunez BS, Vedeckis WV. (2002) Characterization of promoter 1B in the human glucocorticoid receptor gene. Mol Cell Endocrinol. 189, 191–199.PubMedGoogle Scholar
  147. 147.
    Rivers C, Levy A, Hancock J, Lightman S, Norman M. (1999) Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab. 84, 4283–4286.PubMedGoogle Scholar
  148. 148.
    Oakley RH, Sar M, Cidlowski JA. (1996) The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem. 271, 9550–9559.PubMedGoogle Scholar
  149. 149.
    Leung DY, Hamid Q, Vottero A, et al. (1997) Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med. 186, 1567–1574.PubMedGoogle Scholar
  150. 150.
    Christodoulopoulos P, Leung DY, Elliott MW, et al. (2000) Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma. J Allergy Clin Immunol. 106, 479–484.PubMedGoogle Scholar
  151. 151.
    Hamid QA, Wenzel SE, Hauk PJ, et al. (1999) Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med. 159(5 pt. 1), 1600–1604.PubMedGoogle Scholar
  152. 152.
    Hauk PJ, Goleva E, Strickland I, et al. (2002) Increased glucocorticoid receptor Beta expression converts mouse hybridoma cells to a corticosteroid-insensitive phenotype. Am J Respir Cell Mol Biol. 27, 361–367.PubMedGoogle Scholar
  153. 153.
    Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. (2000) Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-iso-form. J Allergy Clin Immunol. 105, 943–950.PubMedGoogle Scholar
  154. 154.
    Lewis-Tuffin LJ, Cidlowski JA. (2006) The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci. 1069, 1–9.PubMedGoogle Scholar
  155. 155.
    Bergeron C, Fukakusa M, Olivenstein R, et al. (2006) Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma. J Allergy Clin Immunol. 117, 703–705.PubMedGoogle Scholar
  156. 156.
    Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY. (2006) Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med. 173, 607–616.PubMedGoogle Scholar
  157. 157.
    Rivers C, Levy A, Hancock J, Lightman S, Norman M. (1999) Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab. 84, 4283–4286.PubMedGoogle Scholar
  158. 158.
    Hurley DM, Accili D, Stratakis CA, et al. (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest. 87, 680–686.PubMedGoogle Scholar
  159. 159.
    Karl M, Lamberts SW, Detera-Wadleigh SD, et al. (1993) Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab. 76, 683–689.PubMedGoogle Scholar
  160. 160.
    Karl M, Lamberts SW, Koper JW, et al. (1996) Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assoc Am Physicians. 108, 296–307.PubMedGoogle Scholar
  161. 161.
    Karl M, Von Wichert G, Kempter E, et al. (1996) Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab. 81, 124–129.PubMedGoogle Scholar
  162. 162.
    Malchoff DM, Brufsky A, Reardon G, et al. (1993) A mutation of the glucocorticoid receptor in primary cortisol resistance. J Clin Invest. 91, 1918–1925.PubMedGoogle Scholar
  163. 163.
    Mendonca BB, Leite MV, de Castro M, et al. (2002) Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene. J Clin Endocrinol Metab. 87, 1805–1809.PubMedGoogle Scholar
  164. 164.
    Ruiz M, Lind U, Gafvels M, et al. (2001) Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol (Oxf). 55, 363–371.Google Scholar
  165. 165.
    Strasser-Wozak EM, Hattmannstorfer R, Hala M, et al. (1995) Splice site mutation in the glucocorticoid receptor gene causes resistance to glucocorticoid-induced apoptosis in a human acute leukemic cell line. Cancer Res. 55, 348–353.PubMedGoogle Scholar
  166. 166.
    Vottero A, Kino T, Combe H, Lecomte P, Chrousos GP. (2002) A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J Clin Endocrinol Metab. 87, 2658–2667.PubMedGoogle Scholar
  167. 167.
    Majnik J, Patocs A, Balogh K, Toth M, Racz K. (2004) A rapid and simple method for detection of Asn363Ser polymorphism of the human glucocorticoid receptor gene. J Steroid Biochem Mol Biol. 92, 465–468.PubMedGoogle Scholar
  168. 168.
    Syed AA, Irving JA, Redfern CP, et al. (2004) Low prevalence of the N363S polymorphism of the glucocorticoid receptor in South Asians living in the United Kingdom. J Clin Endocrinol Metab. 89, 232–235.PubMedGoogle Scholar
  169. 169.
    Lei SF, Deng FY, Liu XH, et al. (2003) Polymorphisms of four bone mineral density candidate genes in Chinese populations and comparison with other populations of different ethnicity. J Bone Miner Metab. 21, 34–42.PubMedGoogle Scholar
  170. 170.
    Echwald SM, Sorensen TI, Andersen T, Pedersen O. (2001) The Asn363Ser variant of the glucocorticoid receptor gene is not associated with obesity or weight gain in Danish men. Int J Obes Relat Metab Disord. 25, 1563–1565.PubMedGoogle Scholar
  171. 171.
    DeRijk R, de Kloet ER. (2005) Corticosteroid receptor genetic polymorphisms and stress responsivity. Endocrine. 28, 263–270.PubMedGoogle Scholar
  172. 172.
    Huizenga NA, Koper JW, De Lange P, et al. (1998) A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab. 83, 144–151.PubMedGoogle Scholar
  173. 173.
    Schaaf MJ, Cidlowski JA. (2002) AUUUA motifs in the 3′UTR of human glucocorticoid receptor alpha and beta mRNA destabilize mRNA and decrease receptor protein expression. Steroids. 67, 627–636.PubMedGoogle Scholar
  174. 174.
    Tantisira KG, Lake S, Silverman ES, et al. (2004) Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 13, 1353–1359.PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Gregory A. Hawkins
    • 1
  • Stephen P. Peters
    • 1
  1. 1.Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Center for Human GenomicsWake Forest University School of MedicineWinston-SalemNorth Carolina

Personalised recommendations